The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes of malignant peripheral nerve sheath tumors in neurofibromatosis type 1 and sporadic patients: A 25-year experience from a sarcoma referral center.
 
Clio Coste
No Relationships to Disclose
 
Mehdi Brahmi
Honoraria - Amgen; PharmaMar
Consulting or Advisory Role - Deciphera; SpringWorks Therapeutics
Expert Testimony - Bayer; Bayer; Deciphera
Travel, Accommodations, Expenses - mundipharma; PharmaMar
 
Franck Tirode
No Relationships to Disclose
 
Armelle Dufresne
Research Funding - Adaptimmune (Inst); Bayer (Inst); GSB Pharma (Inst)
Travel, Accommodations, Expenses - Pfizer; PharmaMar
 
Isabelle Ray-Coquard
Honoraria - Abbvie; Advaxis; AGENUS; Amgen; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Daiichi Sankyo; DECIPHERA; Genmab; GlaxoSmithKline; IMMUNOCORE; Immunogen; Macrogenics; MERSANA; MSD Oncology; Novartis; OxOnc; Pfizer; PharmaMar; PMV Pharma; Roche; Seagen; Sutro Biopharma; Tesaro
Consulting or Advisory Role - Abbvie; AGENUS; AstraZeneca; Blueprint Medicines; BMS; Bristol-Myers Squibb; Clovis Oncology; Corcept Therapeutics; Daichi; Deciphera; Eisai; Genmab; GlaxoSmithKline; Immunocore; Immunogen; Incyte; Lilly; Macrogenics; Mersana; MSD Oncology; Netris Pharma; Novartis; Novocure; Ose pharma; Pfizer; PharmaMar; Roche; Scorpion Therapeutics; seagen; Seagen; Sutro Biopharma; Tesaro
Research Funding - BMS; MSD Oncology; Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Advaxis; AstraZeneca; BMS; Clovis Oncology; Clovis Oncology; GlaxoSmithKline; PharmaMar; Roche; Tesaro
(OPTIONAL) Uncompensated Relationships - Arcagy-Gineco; Belgium health authorities; French National Cancer Institute (INCA); GERMAN health authorities; ITALIAN HEALTH AUTORITIES
 
Jean-Yves Blay
Leadership - Transgene
Honoraria - AstraZeneca; Bayer; BMS; Deciphera; Ignyta; MSD; PharmaMar; Roche
Consulting or Advisory Role - Bayer; Blueprint Medicines; Deciphera; Deciphera; Deciphera; Deciphera; GlaxoSmithKline; Karyopharm Therapeutics; Pharmamar; Roche
Research Funding - AstraZeneca (Inst); Bayer (Inst); BMS (Inst); DEciphera (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis (Inst); OSE Pharma (Inst); Pharmamar (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Roche
 
Mona Amini-Adle
No Relationships to Disclose